Leveraging interacting signaling pathways to robustly improve the quality and yield of human pluripotent stem cell-derived hepatoblasts and hepatocytes.

differentiation disease modeling drug discovery hepatoblasts hepatocyte-like cells human induced pluripotent stem cells liver development liver organoids pluripotent stem cells

Journal

Stem cell reports
ISSN: 2213-6711
Titre abrégé: Stem Cell Reports
Pays: United States
ID NLM: 101611300

Informations de publication

Date de publication:
08 03 2022
Historique:
received: 10 08 2020
revised: 04 01 2022
accepted: 05 01 2022
pubmed: 6 2 2022
medline: 3 5 2022
entrez: 5 2 2022
Statut: ppublish

Résumé

Pluripotent stem cell (PSC)-derived hepatocyte-like cells (HLCs) have shown great potential as an alternative to primary human hepatocytes (PHHs) for in vitro modeling. Several differentiation protocols have been described to direct PSCs toward the hepatic fate. Here, by leveraging recent knowledge of the signaling pathways involved in liver development, we describe a robust, scalable protocol that allowed us to consistently generate high-quality bipotent human hepatoblasts and HLCs from both embryonic stem cells and induced PSC (iPSCs). Although not yet fully mature, such HLCs were more similar to adult PHHs than were cells obtained with previously described protocols, showing good potential as a physiologically representative alternative to PHHs for in vitro modeling. PSC-derived hepatoblasts effectively generated with this protocol could differentiate into mature hepatocytes and cholangiocytes within syngeneic liver organoids, thus opening the way for representative human 3D in vitro modeling of liver development and pathophysiology.

Identifiants

pubmed: 35120625
pii: S2213-6711(22)00047-9
doi: 10.1016/j.stemcr.2022.01.003
pmc: PMC9039749
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

584-598

Subventions

Organisme : CIHR
ID : MY6-155373
Pays : Canada

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Dev Biol. 2013 Dec 15;384(2):155-65
pubmed: 24144921
Nat Commun. 2020 Mar 24;11(1):1537
pubmed: 32210240
Nature. 1995 Feb 23;373(6516):699-702
pubmed: 7854452
Stem Cell Res Ther. 2019 Aug 15;10(1):258
pubmed: 31416480
Hepatology. 2010 May;51(5):1754-65
pubmed: 20301097
Cell Mol Life Sci. 2015 Oct;72(20):3831-51
pubmed: 26089250
Cell Res. 2019 Jan;29(1):8-22
pubmed: 30361550
Curr Drug Metab. 2009 Mar;10(3):307-21
pubmed: 19442091
Nat Genet. 2003 Jul;34(3):292-6
pubmed: 12808453
Hepatol Commun. 2017 Oct 12;1(10):1058-1069
pubmed: 29404442
Development. 2015 Jun 15;142(12):2094-108
pubmed: 26081571
Stem Cell Reports. 2019 Mar 5;12(3):624-638
pubmed: 30773487
Cytotherapy. 2020 Oct;22(10):536-542
pubmed: 32768274
Hepatology. 2018 Feb;67(2):750-761
pubmed: 28834615
Stem Cell Reports. 2016 Oct 11;7(4):802-816
pubmed: 27693424
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Nature. 2013 Jul 25;499(7459):481-4
pubmed: 23823721
Nat Commun. 2017 May 03;8:15166
pubmed: 28466868
Dev Biol. 2008 Jul 15;319(2):234-47
pubmed: 18513713
Science. 2016 Jan 8;351(6269):176-80
pubmed: 26634440
Hepatology. 2010 Jan;51(1):297-305
pubmed: 19998274
Gastroenterology. 2017 Feb;152(3):533-545
pubmed: 28003097
Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18919-23
pubmed: 19033191
Stem Cell Res Ther. 2015 Aug 18;6:144
pubmed: 26282538
J Clin Transl Res. 2018 May 28;4(1):75-100
pubmed: 30873497
Nat Rev Drug Discov. 2004 Aug;3(8):711-5
pubmed: 15286737
Hepatology. 2015 Apr;61(4):1370-81
pubmed: 25421237
Mol Cell Endocrinol. 2001 Feb 14;172(1-2):47-56
pubmed: 11165039
Nat Chem Biol. 2013 Aug;9(8):514-20
pubmed: 23728495
J Hepatol. 2019 Jan;70(1):97-107
pubmed: 30240598
J Hepatol. 2015 Mar;62(3):581-9
pubmed: 25457200
J Cell Physiol. 2019 Feb 15;:
pubmed: 30770551
Toxicol In Vitro. 2016 Jun;33:71-9
pubmed: 26921663
Curr Protoc Stem Cell Biol. 2013 Sep 20;26:1G.4.1-1G.4.13
pubmed: 24510789
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12538-43
pubmed: 22802639
Hepatology. 2004 Sep;40(3):527-36
pubmed: 15349890
EMBO J. 1999 Apr 15;18(8):2127-36
pubmed: 10205167
Stem Cell Reports. 2017 Dec 12;9(6):1813-1824
pubmed: 29173899
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Dev Cell. 2010 Feb 16;18(2):175-89
pubmed: 20159590
Cell Stem Cell. 2017 Apr 6;20(4):547-557.e7
pubmed: 28388431
Development. 2011 Mar;138(5):861-71
pubmed: 21270052
Cell Res. 2019 Sep;29(9):696-710
pubmed: 31270412
Hepatology. 2003 Jun;37(6):1375-84
pubmed: 12774017
Stem Cells. 2007 Jan;25(1):29-38
pubmed: 17204604
Development. 2017 Mar 15;144(6):1056-1064
pubmed: 28275009
Commun Biol. 2020 Nov 3;3(1):642
pubmed: 33144666
Nat Commun. 2018 Oct 22;9(1):4383
pubmed: 30348985
Hepatology. 1988 Nov-Dec;8(6):1586-95
pubmed: 2461337
Curr Drug Metab. 2006 Aug;7(6):629-60
pubmed: 16918317
Stem Cell Reports. 2014 Jun 12;3(1):5-14
pubmed: 25068117
Gastroenterology. 2010 Apr;138(4):1525-35, 1535.e1-6
pubmed: 20080099
Cell Stem Cell. 2014 Mar 6;14(3):394-403
pubmed: 24582926
Nat Genet. 2000 Jul;25(3):254-5
pubmed: 10888866
J Hepatol. 2016 Jun;64(6):1315-26
pubmed: 26921690
Gastroenterology. 2011 Oct;141(4):1432-8, 1438.e1-4
pubmed: 21708104

Auteurs

Claudia Raggi (C)

Liver Tissue Engineering and Cell Therapy Laboratory, CHU Sainte-Justine, Montreal, QC, Canada; Morphocell Technologies Inc., Montreal, QC, Canada.

Marie-Agnès M'Callum (MA)

Liver Tissue Engineering and Cell Therapy Laboratory, CHU Sainte-Justine, Montreal, QC, Canada.

Quang Toan Pham (QT)

Liver Tissue Engineering and Cell Therapy Laboratory, CHU Sainte-Justine, Montreal, QC, Canada.

Perrine Gaub (P)

CHU Sainte-Justine Research Center, Montreal, QC, Canada; Morphocell Technologies Inc., Montreal, QC, Canada.

Silvia Selleri (S)

Liver Tissue Engineering and Cell Therapy Laboratory, CHU Sainte-Justine, Montreal, QC, Canada.

Nissan Vida Baratang (NV)

Morphocell Technologies Inc., Montreal, QC, Canada.

Chenicka Lyn Mangahas (CL)

Liver Tissue Engineering and Cell Therapy Laboratory, CHU Sainte-Justine, Montreal, QC, Canada.

Gaël Cagnone (G)

CHU Sainte-Justine Research Center, Montreal, QC, Canada.

Bruno Reversade (B)

Institute of Molecular and Cell Biology and Institute of Medical Biology, A(∗)STAR, Singapore, Singapore.

Jean-Sébastien Joyal (JS)

CHU Sainte-Justine Research Center, Montreal, QC, Canada; Department of Pediatrics, Université de Montréal, Montreal, QC, Canada.

Massimiliano Paganelli (M)

Liver Tissue Engineering and Cell Therapy Laboratory, CHU Sainte-Justine, Montreal, QC, Canada; Department of Pediatrics, Université de Montréal, Montreal, QC, Canada; Morphocell Technologies Inc., Montreal, QC, Canada; Pediatric Hepatology, CHU Sainte-Justine, Montreal, QC, Canada. Electronic address: m.paganelli@umontreal.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH